TH-302 in Combination With Bevacizumab for Glioblastoma
Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy
bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease
progression.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio